New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn... ( Crohn's disease a chronic inflammator...)

HOME >> MEDICINE >> TECHNOLOGY

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

Date:6/2/2009

Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, affects approximately 500,000 Americans, including approximately 150,000 pediatric patients. The cause of Crohn's disease is not known, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition or diet and other environmental factors. Symptoms of Crohn's disease can vary but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss and fever. There is currently no cure for Crohn's disease.

About REMICADE

REMICADE was the first anti-TNF-alpha treatment to be approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in clinical trials over the past 16 years and through commercial experience with more than one million patients treated worldwide.

In the U.S., REMICADE is approved for the following indications:

Reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA, when administered in combination with methotrexate.
Reducing signs and symptoms in patients with active AS.
Reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active CD who have had an inadequate response to conventional therapy.
Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients wi
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

Post Your Comments:

(Date:5/22/2013)... FRANCISCO, Calif. , May 22, 2013 ... announced the clinical advancement of three programs in development. ... of a JAK/SYK inhibitor, R348, being developed by Rigel ... two programs are aimed at oncology targets and are ... inhibitor under development by BerGenBio AS (BerGenBio) and a ...

(Date:5/22/2013)... May 22, 2013 WomanCare Global recently ... with an extensive training initiative attended by 90 ... http://photos.prnewswire.com/prnh/20130522/DC18844 ) (Logo: http://photos.prnewswire.com/prnh/20101018/DC83896LOGO ) ... a highly effective subdermal implant composed of two ... levonorgestrel (a synthetic form of the hormone progestin). ...

(Date:5/21/2013)... 2013 NxStage Medical, Inc. (Nasdaq: NXTM ... announced that it has entered into new agreements covering ... to DaVita, the kidney care division of DaVita Healthcare Partners ... For the use of products for home hemodialysis ... has executed a second amended and restated National Service ...

Breaking Medicine Technology:Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2 Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3 Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4 WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile 2 NxStage Announces New Agreements with DaVita 2

[0] Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye [0] WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile [0] NxStage Announces New Agreements with DaVita

... /PRNewswire-USNewswire/ -- The Barbara,Ann Karmanos Cancer Institute's Philip ... oncology, presented the outcome,of one of the largest ... America and chaired an education session about the,future ... of,Clinical Oncology (ASCO) annual meeting in Chicago, IL. ...

... 2007 - First-in-human results for,IMC-A12, a monoclonal antibody ... to IGF-1R (insulin-like,growth factor type 1 receptor), were ... of Clinical Oncology in Chicago.,The IGF-IR is expressed ... transmits signals that lead to tumor cell growth ...

Cached Medicine Technology:Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 2 Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 3 Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2 Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3

Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO

(Date:5/22/2013)... 22, 2013 Following the success of ... franchise Fit Body Boot Camp Kincardine has announced ... Meltdown Challenge starting on June 3rd at its ... Durham Street, Kincardine, Ontario. , Fit Body Boot Camp’s ... motivate local community residents to lose a total of ...

(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 ... and management solutions for social enterprise collaboration platforms, ... a consulting firm based in Chicago, Ill. The ... their products and provide best-in-class solutions for SharePoint ... improve collaboration. , AvePoint’s DocAve Software Platform ...

(Date:5/22/2013)... May 22, 2013 Poor adherence to ... not only medical complications and death (some 125,000 deaths ... non-adherence), but increased health-care costs. It’s been estimated that ... are related to poor medication adherence — a reality ... annually. , Indeed, so dire is the degree of ...

(Date:5/22/2013)... 2013 Athletic-Minded Traveler LLC, a ... released today its 2013 U.S. Business Hotel “Fit ... the company’s recommendation after ongoing research of over ... by the editorial staff. Selection criteria included ... court, etc.), in-room workout choices, healthy food offerings, ...

(Date:5/21/2013)... 22, 2013 Swimsuit season is almost here. ... ® products has begun with a 35% discount. , Cellulite ... Many women get the dreaded cellulite even if they are ... skin where they have been stored as toxic lymph and ... easy fixes, a specific program that works to dissolve the ...

Breaking Medicine News(10 mins):Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2 Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2 Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3 Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2 Health News:2013: The 10 Healthiest Business Hotels in the U.S. 2 Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2

[0] Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity [0] AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration [0] Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance [0] 2013: The 10 Healthiest Business Hotels in the U.S.[0] Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale"

... to Health Care Management WASHINGTON, May 5 ... and education organization, announced today that Christine G. Leyden, ... Chief Accreditation Officer for URAC has been recognized as ... in Point magazine. Ms. Leyden will be featured ...

... Education Campaign to Share Her Weight-Loss Journey and Inspire Other ... year, actress Caitlin Van Zandt of "Guiding Light" and "The ... the United States,(1) causing her to also be one of ... at risk of heart disease.(2) Caitlin was at risk of ...

... behind on shots when parents don,t make it to ... Scheduling issues, communication problems and a lack of belief ... some of the biggest hurdles to getting parents to ... report. , Missed appointments were linked to children being ...

... Osteosarcoma is the most common and potentially most dangerous ... of 10 - 25. In "Cancer from A to Z" ... dictionary by Dr. Edward Laughlin, learn that before the 1980,s ... be an intimidating place to enter, and the terminology barrier ...

... Demonstrated in Favorable Response Rates and Hearing PreservationSUNNYVALE, ... ARAY ), a global leader in the ... data using the CyberKnife(R) Robotic Radiosurgery System was ... Association of Neurological Surgeons (AANS) Annual Meeting, May ...

... Help Her get a Good Night,s Sleep at the Samaritan ... This week, sons and daughters all over the community will ... woman in their life - Mom. Flowers, cards and ... are lacking is a good night,s sleep."The need for sleep ...

Case in Point Magazine Names URAC Senior Vice President Leader in Health Care Accreditation Video: New Survey Finds 97 Percent of Women Understand Weight Increases Heart Disease Risk - The Leading Cause of Female Death in the United States - Yet 55 Percent Remain Overweight Keeping Appointments Key to Keeping Vaccines on Track 'Cancer from A to Z': A Dictionary of Cancer-Related Terms Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications What does Mom really want for Mothers Day?

The Storz Protege is an anterior segment unit only....

The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....

Compact ultrasonic phacoemulsification system....

... Precisionist workstation is a unique combination ... allowing infinite flexibility for modular hardware ... the demands of changing cataract surgical ... concept in ophthalmic surgical platforms providing ...

Medicine Products:

Storz Phaco Protige Storz Phaco Premiere Compact Ultrasonic Phacoemulsification System Precisionist Phacoemulsification System